Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Dow
AstraZeneca
Colorcon
Harvard Business School
Mallinckrodt

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050207

See Plans and Pricing

« Back to Dashboard

NDA 050207 describes ERYPED, which is a drug marketed by Arbor Pharms Llc and Arbor Pharms Inc and is included in two NDAs. It is available from three suppliers. Additional details are available on the ERYPED profile page.

The generic ingredient in ERYPED is erythromycin ethylsuccinate. There are one hundred and three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the erythromycin ethylsuccinate profile page.
Summary for 050207
Tradename:ERYPED
Applicant:Arbor Pharms Llc
Ingredient:erythromycin ethylsuccinate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 050207
Suppliers and Packaging for NDA: 050207
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
E.E.S. erythromycin ethylsuccinate GRANULE;ORAL 050207 NDA Arbor Pharmaceuticals, Inc. 24338-130 24338-130-13 100 mL in 1 BOTTLE (24338-130-13)
E.E.S. erythromycin ethylsuccinate GRANULE;ORAL 050207 NDA Arbor Pharmaceuticals, Inc. 24338-132 24338-132-13 100 mL in 1 BOTTLE (24338-132-13)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrengthEQ 200MG BASE/5ML
Approval Date:Approved Prior to Jan 1, 1982TE:AB1RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrengthEQ 400MG BASE/5ML
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrengthEQ 200MG BASE/5ML
Approval Date:Mar 30, 1987TE:AB2RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
AstraZeneca
Mallinckrodt
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.